Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual inhibition of SARS-CoV-2 spike and main protease through a repurposed drug, rutin

27 Dec 2020

Abstract excerpt

The global health emergency caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to alarming numbers of fatalities across the world. So far the researchers worldwide have not been able to discover a breakthrough in the form of a potent drug or an effective vaccine. Therefore, it is imperative to discover drugs to curb the ongoing menace. In silico approaches using FDA approved drugs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to Protein Structure and Dynamics
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33357073
DOI: 10.1080/07391102.2020.1864476

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual inhibition of SARS-CoV-2 spike and main protease through a repurposed drug, rutinPMID 33357073Read ↗

In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19Semantic proximity Read ↗

In-silico analysis of potential interaction of drugs and the SARS-CoV-2 spike proteinSemantic proximity Read ↗

Structure Based Drug Repurposing Through Targeting Nsp9 Replicase and Spike Proteins of SARS-CoV-2Semantic proximity Read ↗

Inhibition potential of natural flavonoids against selected omicron (B.1.19) mutations in the spike receptor binding domain of SARS-CoV-2: a molecular modeling approach.Semantic proximity Read ↗

Discovery of Potential Inhibitors of the Receptor-binding Domain (RBD) of Pandemic Disease-causing SARS-CoV-2 Spike Glycoprotein from Triphala Through Molecular DockingSemantic proximity Read ↗

Shortlisting Phytochemicals Exhibiting Inhibitory Activity against Major Proteins of SARS-CoV-2 through Virtual ScreeningSemantic proximity Read ↗

In Silico Discovery and Evaluation of Inhibitors of the SARS-CoV-2 Spike Protein–HSPA8 Complex Towards Developing COVID-19 Therapeutic DrugsSemantic proximity Read ↗

Molecular Mechanism of Black Tea (Camellia sinensis) as SARS-CoV-2 Spike Glycoprotein Inhibitor through Computational ApproachSemantic proximity Read ↗

Possible SARS-coronavirus 2 Inhibitor Revealed By Simulated Molecular Docking to Viral Main Protease and Host toll-like ReceptorSemantic proximity Read ↗

A rational drug designing: What bioinformatics approach tells about the wisdom of practicing traditional medicines for screening the potential of Ayurvedic and natural compounds for their inhibitory effect against COVID-19 Spike, Indian strain Spike, Papain-like protease and Main Protease proteinSemantic proximity Read ↗

Reframing quercetin as a promiscuous inhibitor against SARS-CoV-2 main proteaseSemantic proximity Read ↗

In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.